UAE – M42 and Japan’s National Institutes for Quantum Science and Technology (QST) have joined forces to drive research into the use of carbon ion therapy for cancer treatments.
As part of this deal, M42 and QST will facilitate different forms of knowledge sharing to accelerate the use of this advanced form of radiation therapy.
Carbon ion therapy has gained significant interest globally due to its advantageous physical and radiobiologic properties compared to photon-based therapy.
Carbon ion radiotherapy has been studied for almost every type of malignancy, including intracranial malignancies, head and neck malignancies, primary and metastatic lung cancers, tumors of the gastrointestinal tract, prostate and genitourinary cancers, sarcomas, cutaneous malignancies, breast cancer, gynecologic malignancies, and pediatric cancers.
M42 and Japan’s National Institutes for Quantum Science and Technology will work closely to develop new approaches to cancer treatment using carbon ion therapy.
It is in line with M42’s commitment to delivering world-class patient-centric care enabled by advanced technologies and innovative solutions.
Commenting on the new venture, Hasan Jasem Al Nowais, Group Chief Executive Officer and Managing Director of M42, said: “We are honored to partner with QST, the leaders in charged particle radiotherapy. It marks a pivotal milestone in our quest to expand clinical research in this field.”
The partnership focuses on technology‐driven research that can help to accelerate the utilization of carbon ion therapy in the fight against cancer.
Moreover, carbon ion therapy treatment has potential advantages over traditional techniques, including better dose escalation to tumors while reducing radiation dose to adjacent normal tissues.
The combination of M42’s unique medical and data-centric technologies and state-of-the-art facilities with QTS’s experience in quantum science and technology will help researchers to gain a deeper understanding and knowledge of the medical use of carbon ion therapy.
“By working hand in hand, we are confident that our collaboration will enable optimal cancer care, further potential clinical indications for carbon ion therapy, and shape the future of healthcare in the region and beyond,” underscored Hasan Jasem Al Nowais.
Radiation therapy is one of the most widely used therapies for malignancies. The therapeutic use of heavy ions, such as carbon, has gained significant interest due to advantageous physical and radiobiologic properties compared to photon-based therapy.
There are currently 16 centers around the world treating with carbon ion radiotherapy. To date, many of these centers have published promising safety and efficacy data from the first cohorts of patients treated.
QST was formed from the merger of the National Institute of Radiological Sciences (NIRS) with certain operations that were previously undertaken by the Japan Atomic Energy Agency (JAEA).
Consequently, the partnership between M42 and QST will build on the ongoing efforts of QST to establish world-leading research and development platforms on the medical use of radiotherapy.
It comes as part of QST’s mission to raise the level of quantum and radiological sciences and technologies, and to ensure research and development delivers significant academic, social, and economic impacts.
This new deal can contribute to further cementing QST’s position as a global center for radiation protection and radiation emergency medicine.
Speaking on the significance of tech-driven research, Shigeo Koyasu, President of QST, stated: “It is wonderful to start research cooperation with M42. This cooperation will promote widespread use of carbon ion radiotherapy and help build a healthy and long-lived society with zero cancer deaths.”
For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.
